Clinical studies support that plasma measures of GFAP correlate with its CSF levels, and are increased in CU individuals with AD pathophysiology, representing a robust proxy of astrocyte reactivity in the brains of living individuals20–22. Here, GFAP is linked to Alzheimer disease.